Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.

J Mol Med (Berl) · 2008 · PMC2491411 · PMID 18504532

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Fusion protein scFv425:sTRAILmR1–5 showed superior apoptotic activity compared to the corresponding wild-type sTRAIL fusion protein on half of the EGFR-positive solid tumor cell lines tested and showed a nonsignificant trend to higher apoptotic activity on the other cell lines.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.